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Celiac disease (CeD) is a common immune-mediated disorder triggered by intake of grain-
derived gluten proteins that affects 1-2% of individuals in the western world. Although the 
precise cause of CeD is unknown, multiple environmental and genetic factors have been 
found to contribute to the development of this complex disease1.
In most CeD patients gluten ingestion triggers a strong immune response that provokes 
the activation of gluten-specific CD4+ T cells, production of anti-transglutaminase 2 (TG2) 
antibodies by B cells and lymphocyte infiltration in the small intestine, and all these processes 
contribute to the villous atrophy and crypt hyperplasia characteristic of the disease. As a 
result, CeD patients have a variable degree of small intestinal inflammation and a broad 
range of manifestations that include diarrhea, abdominal pain and malabsorption2. In addition 
to the classical gastrointestinal symptoms, CeD patients can also present extra-intestinal 
manifestations such as anemia3, osteoporosis4, dermatitis herpetiformis5 and neurological 
disorders6. Because of this wide range of symptoms, it is thought that many cases of CeD go 
undiagnosed7. 
Currently, a lifelong gluten-free diet (GFD) is the only available treatment for CeD. Avoidance 
of gluten contributes to the recovery of the intestinal mucosa, the reduction of levels of 
anti-TG2 antibodies and eventually to reduction of symptoms8. In spite of its benefits, a 
GFD can be challenging to maintain due to multiple factors, including social restrictions, 
nutrient deficiencies and high costs8,9. In addition, a small sub-group of patients (1-5%) fail 
to respond to a GFD, and these individuals are at risk of developing a severe condition 
called refractory celiac disease (RCD) that is characterized by a remarkable infiltration of 
intraepithelial cytotoxic T cells (IE-CTLs) with abnormal phenotype. In RCD these intestinal 
abnormalities persist and can eventually contribute to the development of enteropathy-
associated T cell lymphoma10. 
Although gluten exposure is the most important environmental factor in CeD pathogenesis, 
recent evidence implicates other environmental factors in disease development. Intestinal 
viral infections and bacterial microbiota have been linked to CeD as possible environmental 
triggers1,11,12. In a recent study Bouziat et al. suggested that reovirus infection induces 
a proinflammatory response with a concomitant loss of oral tolerance to gluten13, while 
the involvement of the bacterial microbiome has been suggested by studies reporting gut 
microbiome dysbiosis in CeD patients as compared to healthy individuals14,15. Interestingly, 
these CeD-associated changes in microbiota composition have been shown to affect the 
processing of gluten peptides16, which may affect gluten presentation to gluten-specific 
CD4+ T cells and thereby increasing the inflammatory response. Thus, in addition to 
gluten, environmental factors such as the gut microbiome and virome may contribute to the 
environmental component of the risk of developing CeD, although their respective contributions 
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to CeD development are still unclear1,11,13. In contrast, genetic risk factors have been estimated 
to contribute approximately 50% of CeD risk, making them the major predisposing factors 
currently known for CeD1,17.
Genetic risk factors
The strongest genetic factor associated to CeD risk is the human leukocyte antigen (HLA) 
region. More than 90% of CeD patients carry either the HLA-DQ2 (HLA-DQ2.5) or the HLA-
DQ8 allele, and these alleles appear to account for up to 40% of the genetic risk of developing 
the disease18. However, although the absence of these alleles in individuals means they will 
not get the disease, their presence alone cannot predict who will develop CeD because these 
alleles are present in approximately 30-40% of the general population. This suggests that, 
while the HLA-DQ2 and -DQ8 alleles are necessary for CeD development, additional genetic 
factors are required19. To date, genome-wide association studies (GWAS) have identified 42 
non-HLA genetic variants to be associated with CeD (Fig. 1)17,20. Due to the modest effect 
of each non-HLA variant on overall disease risk, these together account for approximately 
15% of heritability20. Interestingly, most of these genetic variants are also shared with other 
Figure 1. Manhattan plot showing the results of association for 39 of 42 non-HLA CeD risk loci. Known loci 
(black), novel loci (blue) and risk loci with multiple signals (underlined) are depicted. The vertical line represents the 














































































immune-mediated disorders such as rheumatoid arthritis21 (RA) and type I diabetes22 (T1D), 
indicating the presence of a common etiological component in immune-mediated complex 
diseases.
Although GWAS have been very successful in associating genomic loci with disease, there 
is a need for follow-up studies aimed at pinpointing causal genetic variants (single nucleotide 
polymorphisms, SNPs) and genes in these loci23. There are still some limitations that 
prevent successful identification of causal SNPs24. First, due to linkage disequilibrium, many 
adjacent SNPs are co-inherited and are likely to have a similar association or correlation, 
which complicates prioritisation23. Second, in only four of the CeD-associated loci – MMEL1, 
SH2B3, NCF2 and IRAK – do the SNPs affect protein encoding regions25–27. Most of the risk 
SNPs associated with CeD (and complex immune-mediated diseases in general) fall in non-
coding regions of the genome, including intergenic regions, and their consequence is not 
understood28,29. In complex diseases it has consistently been found that these variants are 
enriched in regulatory domains controlling gene expression, including promoter and enhancer 
elements characterized by regions of open chromatin and specific histone modifications30. 
This indicates that, rather than altering protein function, risk SNPs associated with immune 
diseases control the expression of genes encoding proteins or non-coding RNAs. 
To overcome the difficulties discussed above, complementary methods are applied to move 
from SNP associations to the downstream consequences on gene expression and the 
regulation of biological pathways. Zooming in on GWAS loci via fine-mapping, for instance, 
can identify smaller regions that encompass smaller groups of variants with the highest 
probability of causality24. The functional impact of fine-mapped SNPs can then be tested by 
assessing the correlation between expression and genotype (quantitative trait locus (eQTL) 
analysis)31; the interaction between GWAS SNPs and other genomic regions (chromatin 
interaction conformation assays (3C,4C))32; the enrichment-overlap with functional elements 
such as enhancers and promoters (using data generated by the ENCODE33 or Epigenome 
roadmap projects)33 and the potential alterations of transcription factor binding sites23. These 
approaches have confirmed that CeD-associated SNPs affect gene expression rather than 
change the amino acid sequence of proteins17. Additionally, application of computational 
approaches such as gene set enrichment analysis and gene network analysis to genes 
differentially expressed in CeD can elucidate the biological pathways and tissues where these 
risk genes play a role in disease pathophysiology34, and the prioritized set of candidate genes 
that results can then be further validated by in vitro and in vivo assays24. 
From SNPs to disease mechanisms
It has been hypothesized that the intestinal barrier is compromised in CeD35, thereby facilitating 
the passage of gluten peptides into the lamina propria, where they are deaminated by tissue 
TG2. This deamination process strongly increases the binding affinity of gluten peptides to 
HLA-DQ2 or -DQ8 molecules on the surface of antigen presenting cells (APCs) such as 
13
General Introduction
dendritic cells, B cells and macrophages36,37. The gluten peptides presented in the context 
of HLA-DQ2 or -DQ8 are recognized by gluten-specific CD4+ T cells, leading to activation 
of the inflammatory response characteristic of CeD. Upon activation, CD4+ T cells release 
cytokines such as IFNg and IL-2138,39. IL-21 may provide inflammatory signals to B cells 
and intraepithelial cytotoxic T cells (IE-CTLs). B cell activation results in the secretion of 
antibodies against gluten and TG240. However, the clinical implications and pathogenic role 
of these antibodies are still unclear. IFNg promotes the Th-1 immune response, activation of 
APCs and licensing of IE-CTLs to kill intestinal epithelial cells (Fig. 2)40.
A recently performed genetic study integrated different layers of genomic information, 
including eQTL analysis, cell-type-specific enhancer enrichment, functional annotation of 
GWAS SNPs and co-expression analyses41. In addition to confirming what was already known 
about the involvement of the immune system in CeD, this study provided genetic evidence for 
Figure 2. Main players in CeD pathogenesis. A compromised intestinal barrier in predisposed individuals allows the 
passage of gluten peptides into the lamina propria, where the gluten peptides are deaminated by TG2, which enhances 
their affinity for HLA-DQ2 or HLA-DQ8 molecules on the surface of APC (dendritic cells, B cells, macrophages). Presen-
tation to gluten-specific CD4+ T cells results in activation and proliferation of these cells, which then release IFNg and 
IL-21. These cytokines provide signals that enhance the cytolytic properties of IE-CTLs and promote the differentiation 
of B cells towards plasma cells that produce anti-gluten and anti-TG2 antibodies. Some of the environmental factors 
(gluten, microbiome, infections) that can influence the disease onset are indicated. Cytokines/inflammatory molecules 
expressed by intestinal epithelial cells are depicted (IL-15, IFN-1), as are intestinal epithelial cells (IEC), intraepithelial 




























the involvement of the adaptive immune system via the IFNg signaling pathway (although the 
IFN locus itself has not been associated with CeD) and a role for B cells in CeD. Moreover, 
the same study prioritized several genes (LPP, C1orf106) in CeD-associated loci that might 
contribute to decreased intestinal barrier function41. Disturbance of intestinal permeability 
could not only facilitate the passage of gluten into the lamina propria but also that of infectious 
agents. This would boost the presentation of gluten peptides to CD4+ T cells, resulting in 
the release of pro-inflammatory signals, and these processes would contribute to a stronger 
immune response16. Although this evidence suggests that barrier dysfunction can contribute 
to CeD onset35,41, it is still unclear whether this is a primary defect and a cause that contributes 
directly to disease onset or of it is a consequence of the inflammatory environment in the gut 
of CeD individuals42. 
In addition to dysregulation of the adaptive immune system and adaptive cytokines, innate 
cytokines such as IL-15 and IFN type I (IFN-1) are upregulated in intestinal epithelial cells 
of CeD patients43,44. These cytokines enhance the cytolytic and proinflammatory properties 
of CTLs and dendritic cells43–45, respectively. Simultaneously, an induction of stress-induced 
non-classical major histocompatibility complex class I molecules is observed on the surface 
of epithelial cells, which are recognized by natural killer receptors expressed on IE-CTLs. 
This interaction licenses IE-CTLs to kill intestinal epithelial cells, thus contributing to villous 
atrophy46. These findings demonstrate the involvement of both adaptive cytokines (IFNg and 
IL-21) and tissue-derived cytokines (IL-15 and IFN-1) in activation of CTLs. To date, little is 
known about the signaling processes elicited in IE-CTLs by these cytokines47.  
In the work described in this thesis, we have studied how CeD-associated genetic variation can 
be translated to molecular culprits (genes, pathways and relevant cell types). One of the most 
exciting discoveries of genomics research using next generation sequencing methodologies 
has been the existence of a novel class of genes that are transcribed but not translated: long 
non-coding RNAs (lncRNAs). Our group found genetic evidence that, in loci associated with 
Figure 3. Overview of the cell types and methods used in this thesis. A) Human-derived primary and immortalized 
cell lines and culture systems (2D and 3D). B) Tools to target genes and mimic inflammation. C) Lab approaches. D) Data 
analysis strategies, in silico tools, datasets and population cohorts employed to conduct this study
Cell types and culture 
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complex diseases including CeD, lncRNAs are affected by disease-associated SNPs48. Thus, 
it is not only non-coding regulatory elements, but also lncRNAs, that may contribute to the 
deregulation caused by CeD-associated variants. 
In the research leading to this thesis I made use of in silico approaches in combination 
with in vitro experiments in human-derived cells exposed to conditions that resemble the 
inflammatory environment in the intestine of CeD patients in order to prioritize genes and 
lncRNAs potentially involved in CeD and to further understand their role in disease onset and 
pathogenesis (Fig. 3).
Aim and outline of the thesis 
The aim of this thesis is to gain further insights into the function of some of the CeD candidate 
genes and the molecular pathways and mechanisms that play a role in CeD. The candidate 
genes have been selected by in silico and omics approaches in cell types known to play a role 
in CeD pathophysiology. 
As was described above, it has been hypothesized that CeD patients have an inherent barrier 
function defect that could facilitate gluten transport into the lamina propria. Previously, LPP 
has been identified as one of multiple CeD-associated genes that may be involved in cell-cell 
interaction and intestinal barrier homeostasis. In CeD biopsies, LPP expression is reduced 
when compared to normal biopsies. In Chapter 2, we examined whether a reduction in LPP 
does lead to decreased barrier homeostasis using the Caco-2 cell line, which is widely used in 
barrier function and pharmacology research, as an in vitro model. We generated a stable LPP 
knockdown cell line of the parental Caco-2 cell line and evaluated the effect on proliferative 
capacity, permeability and lumen formation in 2D and 3D culture environments. Moreover, we 
evaluated the transcriptional response in this cell line under standard culture conditions and 
upon challenge with IFNg, a cytokine known to be involved in the pathogenesis of CeD. 
During the course of my thesis research, population cohort studies became available that 
could be used for eQTL analysis. Additionally, novel statistical genetics approaches were 
developed in our lab or published by others that could be applied to the data generated in 
the cohort studies to prioritize culprit SNPs and genes in disease-associated loci. In Chapter 
3 we applied a systematic approach to integrate eQTL data from the BIOS cohort (total RNA 
transcriptomics from whole blood of 4000 participants from general population cohorts)49 
with CeD association data derived from the most recent CeD GWAS meta-analysis50. We 
applied four different in silico approaches (LD-overlap, Bayesian co-localization, Mendelian 
randomization and DEPICT) to prioritize potential causal genes, resulting in the identification 
of 126 positional and functional candidate genes. Co-expression and pathway analysis were 
applied to prioritize the main cell types and biological pathways in which these genes are 








The pro-inflammatory response elicited by gluten in CeD patients ultimately converges on 
IE-CTLs that are consequently licensed to kill epithelial cells. Although several key CeD-
associated cytokines are known to affect IE-CTLs, little is known about the transcriptional 
programs triggered by these cytokines. In Chapter 4 we generated TCRab+ CD8+ cytotoxic T 
cell lines from human small intestinal epithelium to study the dynamics of the transcriptional 
response and of genome-wide H3K27 acetylation (H3K27ac) changes in response to 
stimulation with tissue-derived cytokines, also known as alarmins (IFNb and IL-15) or a T 
cell–derived cytokine (IL-21). These three cytokines have not only been associated with tissue 
destruction in CeD, but also with other autoimmune disorders with tissue-specificities such 
as RA, inflammatory bowel disease (IBD) and T1D. The data we generated was analyzed in 
depth to describe the biological pathways that are triggered in IE-CTLs in response to tissue-
derived cytokines versus T cell–derived cytokines. We further studied the relation between 
gene expression and epigenomic (H3K27ac) profiles to get a better understanding of the 
potential mechanism of gene regulation. Finally, we tested the potential enrichment of genes 
responding to cytokine stimulation in risk loci associated with autoimmune diseases (GWAS 
data) to identify genes that might contribute to immune deregulation in IE-CTLs. 
The next generation sequencing and genomics revolution has led to the discovery of novel 
classes of genes and novel insights into disease biology. A significant portion of the SNPs 
associated with complex immune-mediated diseases have been shown to overlap with DNA 
motifs that control the expression or binding sites of micro-RNAs (miRNAs) or to intersect 
gene regulatory motifs of lncRNAs. Chapter 5 is an overview of the general features of these 
two classes of non-coding RNAs in terms of synthesis, structure and the potential mechanism 
by which they modulate gene expression or other processes in the cell. This review focusses 
on the role of these genes in different cells of the adaptive and the innate immune system, 
and on their involvement in immune mediated disorders such as CeD, IBD and multiple 
sclerosis. Chapter 6 focuses on a single lncRNA, lncRNA RP11-291B21.2, that is strongly 
modulated in response to TCR activation in CD8+ T cells, including IE-CTLs. We describe 
the expression pattern of this lncRNA in different CD8+ T cell populations derived from blood 
and infer its potential biological function using single cell RNA-seq data and co-expression 
network analysis. Finally, knockdown experiments performed in IE-CTL cell lines and RNA 
sequencing data were interrogated to provide additional clues for pinpointing this lncRNA’s 
function in IE-CTLs, which are the effector cell type in CeD. 
Chapter 7 summarizes the major findings of this thesis research project and sets them in 
a broader perspective by discussing their implications in the context of CeD and immune-
mediated disorders in general. The main drawbacks and limitations of our experimental 
approaches are described, as are directions and suggestions for how to dig deeper into the 
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